Literature DB >> 16114275

Acid-labile subunit deficiency: phenotypic similarities and differences between human and mouse.

H M Domené1, S V Bengolea, H G Jasper, Y R Boisclair.   

Abstract

IGF-I and IGF-II (IGFs) form higher molecular weight complexes with specific binding proteins (IGFBP-1 to -6). These complexes are referred to as binary complexes consisting of IGF-I or IGF-II and one IGFBP, or as ternary complexes each consisting of either of IGF-I or IGF-II, IGFBP-3 or -5, and an acid-labile subunit known as ALS. Ternary complex formation restricts the IGFs to the circulation and prolongs their half-life. Recently, the development of an animal model for ALS deficiency (the ALS-KO mouse) and the identification of a patient with an inactivating mutation in the IGFALS gene have provided the opportunity to assess the physiological role of this protein in the circulating IGF system. ALS deficiency has no effect on fetal growth in both the ALS-KO mice and the ALS-deficient patients. A modest reduction in post-natal growth in the null ALS mice and in the ALS-deficient patients was observed. The plasma concentrations of IGF-I and IGFBP-3 were markedly reduced both in ALS-KO mice and in the ALS-deficient patients. Basal GH levels remained normal in the ALS-KO mice and moderately increased in the ALS-deficient patients. Insulin-resistance was present in the ALS-deficient patients but not in the ALS-KO mice. Reduced bone mineral density (BMD) was present in mice and human ALS deficiency. Phenotypic features of complete ALS deficiency, that are very similar in mouse and human, include: a) the inability to form ternary complex, b) the small growth impairment in spite of the marked reduction in circulating IGF-I, and c) the reduction in BMD. On the other hand, insulin resistance and pubertal delay were observed only in human ALS deficiency. These findings underlie the important physiological role of ALS in the maintenance of the circulating IGF-I reservoir. Both models will be useful in identifying the respective roles of plasma and locally derived IGF-I in regulating metabolism and growth of specific tissues.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16114275

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  20 in total

Review 1.  Growth hormone insensitivity: diagnostic and therapeutic approaches.

Authors:  S Kurtoğlu; N Hatipoglu
Journal:  J Endocrinol Invest       Date:  2015-06-11       Impact factor: 4.256

2.  Sex-specific regulation of body size and bone slenderness by the acid labile subunit.

Authors:  Hayden-William Courtland; Victoria DeMambro; Jane Maynard; Hui Sun; Sebastien Elis; Clifford Rosen; Shoshana Yakar
Journal:  J Bone Miner Res       Date:  2010-09       Impact factor: 6.741

3.  Insulin-like growth factor 1 treatment extends longevity in a mouse model of human premature aging by restoring somatotroph axis function.

Authors:  Guillermo Mariño; Alejandro P Ugalde; Alvaro F Fernández; Fernando G Osorio; Antonio Fueyo; José M P Freije; Carlos López-Otín
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-30       Impact factor: 11.205

4.  Quantitative ontogeny of murine insulin-like growth factor (IGF)-I, IGF-binding protein-3 and the IGF-related acid-labile subunit.

Authors:  David L Hwang; Phillip D K Lee; Pinchas Cohen
Journal:  Growth Horm IGF Res       Date:  2007-08-23       Impact factor: 2.372

Review 5.  Targeting insulin-like growth factor-I and insulin-like growth factor-binding protein-3 signaling pathways. A novel therapeutic approach for asthma.

Authors:  Hyun Lee; So Ri Kim; Youngman Oh; Seong Ho Cho; Robert P Schleimer; Yong Chul Lee
Journal:  Am J Respir Cell Mol Biol       Date:  2014-04       Impact factor: 6.914

6.  The insulin-like growth factor-1 binding protein acid-labile subunit alters mesenchymal stromal cell fate.

Authors:  J Christopher Fritton; Yuki Kawashima; Wilson Mejia; Hayden-Williams Courtland; Sebastien Elis; Hui Sun; Yinjgie Wu; Clifford J Rosen; David Clemmons; Shoshana Yakar
Journal:  J Biol Chem       Date:  2009-12-10       Impact factor: 5.157

7.  Serum complexes of insulin-like growth factor-1 modulate skeletal integrity and carbohydrate metabolism.

Authors:  Shoshana Yakar; Clifford J Rosen; Mary L Bouxsein; Hui Sun; Wilson Mejia; Yuki Kawashima; Yingjie Wu; Kelly Emerton; Valerie Williams; Karl Jepsen; Mitchell B Schaffler; Robert J Majeska; Oksana Gavrilova; Mariana Gutierrez; David Hwang; Patricia Pennisi; Jan Frystyk; Yves Boisclair; John Pintar; Héctor Jasper; Horacio Domene; Pinchas Cohen; David Clemmons; Derek LeRoith
Journal:  FASEB J       Date:  2008-10-24       Impact factor: 5.191

8.  Bioinformatic analysis of benzo-α-pyrene-induced damage to the human placental insulin-like growth factor-1 gene.

Authors:  A Fadiel; B Epperson; M I Shaw; A Hamza; J Petito; F Naftolin
Journal:  Reprod Sci       Date:  2013-01-23       Impact factor: 3.060

Review 9.  Unraveling insulin-like growth factor binding protein-3 actions in human disease.

Authors:  Sherryline Jogie-Brahim; David Feldman; Youngman Oh
Journal:  Endocr Rev       Date:  2009-05-28       Impact factor: 19.871

10.  Ablation of Hepatic Production of the Acid-Labile Subunit in Bovine-GH Transgenic Mice: Effects on Organ and Skeletal Growth.

Authors:  Zhongbo Liu; Tianzhen Han; Shannon Fishman; James Butler; Tracy Zimmermann; Frederic Tremblay; Carole Harbison; Nidhi Agrawal; John J Kopchick; Mitchell B Schaffler; Shoshana Yakar
Journal:  Endocrinology       Date:  2017-08-01       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.